Biocon Biologics Integrates Viatris Business As It Introduces Adalimumab
Completes ‘First Wave’ Of Viatris Integration And Launches US Hulio Rival To Humira
In a busy couple of weeks for Biocon’s biosimilars unit, the firm has completed the “first wave” of integration for the business it acquired from Viatris, while also launching its US adalimumab biosimilar amid heavy competition.
